More Details on This News

CORONA Remedies Limited announced its unaudited standalone and consolidated financial results for the second quarter and half year ended September 30, 2025. The company's Board of Directors approved these results.

The consolidated revenue from operations for Q2 FY26 stood at ₹361.13 crore, marking a year-on-year growth of 15.1%. For the half year ended September 30, 2025 (H1 FY26), the revenue was ₹707.67 crore, showing a 17.0% year-on-year increase.

Profit After Tax (PAT) for Q2 FY26 was ₹52.32 crore, a 21.8% rise compared to the same period last year. For H1 FY26, PAT reached ₹98.52 crore, an impressive growth of 35.1% year-on-year. EBITDA for the quarter was ₹78.47 crore, and for the half year, it was ₹148.25 crore.

Mr. Nirav K. Mehta, Managing Director and CEO, expressed delight with the strong financial performance, stating that the company outperformed the IPM growth. He attributed the success to a consistent strategy, disciplined execution, and a focus on core therapeutic segments, along with strengthening the field force and expanding the brand portfolio. He also acknowledged the bankers for their role in the company's successful listing.

The company will publish an advertisement for these results in accordance with listing regulations and also made them available on its website, www.coronaremedies.com.

CORONA Remedies Limited will host an earnings call on January 05, 2026, at 12:00 PM IST to discuss the financial and business performance.